In contrast, MAGEA3 exhibited a more consistent correlation with bevacizumab resistance across different samples, suggesting that MAGEA3 may have a more stable prognostic effect than VEGF in CRC patients. The gene discussed is VEGFA; the disease is colorectal carcinoma.